Avenue Therapeutics, Inc.

NasdaqCM:ATXI Stock Report

Market Cap: US$3.4m

Avenue Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Alix MacLean

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage33.0%
CEO tenure2.3yrs
CEO ownershipn/a
Management average tenure2.5yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Avenue Therapeutics shares slide on pricing $12M securities offering

Oct 07

Avenue Therapeutics up 4% on 1-for-15 reverse stock split

Sep 22

Avenue Therapeutics shares fall after FDA declines to approve IV tramadol pain medicine

Jun 14

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Mar 19
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

Jan 23
How Many Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares Do Institutions Own?

We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Dec 19
We're Keeping An Eye On Avenue Therapeutics' (NASDAQ:ATXI) Cash Burn Rate

Avenue Therapeutics issues regulatory update for IV tramadol

Dec 17

CEO Compensation Analysis

How has Alix MacLean's remuneration changed compared to Avenue Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$1mUS$400k

-US$10m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$516kUS$154k

-US$4m

Compensation vs Market: Alix's total compensation ($USD1.21M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Alix's compensation has increased whilst the company is unprofitable.


CEO

Alix MacLean (57 yo)

2.3yrs

Tenure

US$1,213,200

Compensation

Dr. Alexandra MacLean, also known as Alix, MD, serves as Director of Kent Imaging Inc. since January 2021. She is Chief Executive Officer at Avenue Therapeutics, Inc. since August 01, 2022 and serves as it...


Leadership Team

NamePositionTenureCompensationOwnership
Alexandra MacLean
CEO & Director2.3yrsUS$1.21mno data
David Jin
Interim CFO2.8yrsUS$260.00kno data
Lindsay Rosenwald
Executive Director1.8yrsUS$104.00k0.24%
$ 8.3k
Scott Reines
Interim Chief Medical Officer8.9yrsUS$123.12kno data

2.5yrs

Average Tenure

63yo

Average Age

Experienced Management: ATXI's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexandra MacLean
CEO & Director1.8yrsUS$1.21mno data
Lindsay Rosenwald
Executive Director9.8yrsUS$104.00k0.24%
$ 8.3k
Jay Kranzler
Chairman of the Board7.8yrsUS$212.19k0.029%
$ 989.4
Neil Herskowitz
Non-Executive Independent Director9.3yrsUS$164.00k0.0051%
$ 171.5
Faith Charles
Independent Director2.6yrsUS$154.00kno data
Curtis Oltmans
Independent Director3.7yrsUS$154.00k0.0023%
$ 77.8

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: ATXI's board of directors are considered experienced (5.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:14
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avenue Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Antonio ArceH.C. Wainwright & Co.
Jason McCarthyMaxim Group